{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '30. Serum (two 5.0 mL samples) will be obtained on Day 1 and Weeks 12 and 24 of the Treatment Period for possible analysis of interleukin (IL)-4 IL-6, IL-10, IL-12, IL-13,', 'IL-17, IL-23, IL-1B, sIL-1RA, INFy, TGF\u00df, TNFa, micRNA and TSH-R-Ab. Based on the results of the above assays, other similar serum biomarkers may be assayed to', 'further explore drug and disease mechanisms.', '31. PK samples will be collected prior to, and at the end of, the infusion on Day 1 and Weeks 3 and 9 of the Treatment Period; additional single samples will be collected at', 'Weeks 1, 4, and 24.', '32. If TED treatment has been received since last contact, the subject will be questioned regarding type of treatment and outcome/response.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 32 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '3', 'TABLE OF CONTENTS', '1', 'TITLE PAGE', '2', '2', 'SYNOPSIS', '22', '2.1', 'Schedule of Assessments', '29', '3', 'TABLE OF CONTENTS', '33', '4', 'LIST OF ABBREVIATIONS', '39', '5', 'ETHICS', '42', '5.1', 'Institutional Review Board/Independent Ethics Committee', '42', '5.2', 'Ethical Conduct of the Study', '42', '5.3', 'Subject Information and Consent', '42', '5.4', 'Compensation for Health Damage of Subjects/Insurance', '43', '5.5', 'Confidentiality', '43', '6', 'INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE', '43', '7', 'INTRODUCTION', '45', '7.1', 'Background', '45', '7.1.1', 'Thyroid Eye Disease', '45', '7.1.2', 'Insulin-like Growth Factor-1 Receptor (IGF-1R)', '48', '7.1.3', 'Teprotumumab', '49', '7.1.3.1 Physiochemical Properties', '49', '7.1.3.2 Safety Pharmacology', '50', '7.1.3.3 Non-Clinical Pharmacokinetics', '51', '7.1.3.4 Clinical Experience', '52', '7.1.3.4.1', 'Introduction', '52', '7.1.3.4.2', 'Efficacy', '53', '7.1.3.4.3', 'Pharmacokinetics', '53', '7.1.3.4.4', 'Pharmacodynamic Markers', '55', '7.1.3.4.5', 'Safety', '55', '7.2', 'Rationale for this Study', '61', '7.3', 'Rationale for Dose Selection', '62', '8', 'STUDY OBJECTIVES', '62', '8.1', 'Primary Objective', '62', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 33 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '8.2', 'Secondary Objectives', '63', '8.3', 'Exploratory Objectives', '63', '9', 'INVESTIGATIONAL PLAN', '64', '9.1', 'Overall Study Design and Plan', '64', '9.2', 'Discussion of Study Design', '65', '9.3', 'Selection of Study Population', '66', '9.3.1', 'Inclusion Criteria', '66', '9.3.2', 'Exclusion Criteria', '67', '9.3.3', 'Removal of Subjects from Therapy or Assessment', '68', '9.3.4', 'Criteria for Responders Who Relapse', '70', '9.3.5', 'Replacement Policy', '70', '9.3.5.1', 'Subjects', '70', '9.3.5.2', 'Centers', '70', '9.3.5.3', 'Screen Failures', '70', '9.4', 'Treatments', '70', '9.4.1', 'Treatments Administered', '70', '9.4.2', 'Identity of Investigational Products', '71', '9.4.2.1 Teprotumumab', '71', '9.4.2.2 Placebo', '71', '9.4.3', 'Labeling', '71', '9.4.4', 'Storage', '71', '9.4.5', 'Drug Accountability', '72', '9.4.6', 'Study Drug Administration and Timing of Dose for each Subject', '72', '9.4.6.1 Description of Clinical Supplies', '72', '9.4.6.2 Determination of Dose Volume', '72', '9.4.6.3 Details Concerning Timing and Dose Administration', '73', '9.4.6.3.1', 'Preparation and Administration of Teprotumumab', '73', '9.4.6.3.2', 'Dose Modifications, Interruptions, and Delays', '74', '9.4.7', 'Method of Assigning Subjects to Treatment Groups', '75', '9.4.8', 'Masking and Unmasking', '75', '9.4.9', 'Concomitant Therapy and Restricted Medications', '76', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 34 of 117']\n\n###\n\n", "completion": "END"}